On 4 June, 2021, Pharmaxis (ASX: PXS) hosted an investor briefing with CEO Gary Phillips to update investors on recent achievements and future plans, plus a Q&A with attendees.
Topics discussed in the briefing and question time included:
Company Summary
Pharmaxis is in a rare microcap air for a pharmaceutical research company that has a commercialised product at market with sales nearing profitability that can fund transformational cancer research. Addressing a substantial market opportunity through targeting of myelofibrosis where current treatment standards are limited, yet still sell upwards of USD $1 billion per year.
In May 2021, Emerald Financial published a research report on Pharmaxis which can be downloaded here.
Biotech company Biotron Limited (ASX:BIT) has announced a bold step into the anaesthetics sector, acquiring…
DroneShield (ASX:DRO) is expanding its Australian footprint with a $13 million investment to establish a…
Australian fintech Stakk (ASX:SKK) has signed a three-year agreement with U.S. telecommunications giant T-Mobile USA,…
Australia’s mental health burden is growing – and one of the toughest challenges is treatment-resistant…
NoviqTech Limited (ASX:NVQ) has taken a decisive step into the quantum computing market, unveiling the…
Brazilian Rare Earths Limited (ASX:BRE) has cleared its last regulatory hurdle to begin pilot operations…